Shrnutí - 10 let existence

THE CZECH MYELOMA GROUP - INTRODUCTION AND HISTORICAL OVERVIEW

The Czech Myeloma Group (CMG) was established in 1996. The main objective of the CMG is to organize and coordinate research and clinical activities in the Czech Republic in the area of multiple myeloma. It ensures that the best current standards of care for patients with multiple myeloma are met. Its clinical studies provide the Czech patients with multiple myeloma the access to the latest experimental treatments in the field.

As the activities spread out, The Czech Myeloma Group Foundation was established in 2001 to give support to patient related activities and promotions.

All activities of The CMG and of its Foundation are directed at improvements of the treatment of multiple myeloma in the Czech Republic. Also, both organizations aim to provide a relief from the many problems and conditions that limit the quality of life of patients suffering from multiple myeloma.

FUNDAMENTAL PHILOSOPHY OF THE CMG AND THE CMG FOUNDATION

The CMG is an association of physicians and other researchers with main interest in scientific investigation, diagnostics and therapy of multiple myeloma and monoclonal gammopathy.

Goals:

• creation of conjunctive treatment protocols
• running of clinical trials
• bringing new knowledge to the diagnostics, treatment and education

The CMG Foundation is an association of healthcare givers formed to meet the special needs of patients suffering from multiple myeloma, their families and friends.

Goals:

• improving communication with patients with multiple myeloma and their relatives
• establishing collaboration among researchers and clinicians working in the field
• support of preclinical and clinical research in the field of multiple myeloma

THE CMG AND THE CMG FOUNDATION ACTIVITIES

Concentration on physicians and professional community

• improving of functional network of specialized centres for the patients with multiple myeloma
• closer connection between regional health services and specialized reference centres
• holding of seminars, symposia, consultations, and other educational activities
• publishing of guidelines and specialized books
• reference centres provided with data managers and research nurses

Concentration on the patients

• education and better awareness of the patients and their relatives
• HOT LINE and patient section on web sites
• printed information - brochures, leaflets
• educational seminars
• nurse specialists in the reference centres
• benefit performances (vernissage, exhibitions, auction-sales, theatre performance)
• access to the latest treatments in the field (clinical trials)

Concentration on research

The preclinical research was focused mainly on immunotherapy, development of anti-tumor vaccines respectively in the period 1998-2002. More complex research program, established in the year 2002, finally led to opening new Monoclonal Gammopathy and Multiple Myeloma Basic Research Centre in Brno as the reference research centre of The Czech Myeloma Group. This centre works closely with academic field and participates in clinical activities of the Czech Myeloma Group which gives a great opportunity to promote research on multiple myeloma and monoclonal gammopathy. The centre connection with academic field and coordination with clinical activities of The Czech Myeloma Group gives a great opportunity to reinforce research of multiple myeloma and monoclonal gammopathy. The main research projects are focused on pharmocogenomics and proteomics.  

The clinical research is mainly directed at the autologous transplantation and the role of maintenance and/or consolidation therapy. It is also focused on the re-transplantation for relapsed patients and on the phase I / II studies using anti-tumor vaccines.

PRESENT PROJECTS AND PLANS FOR THE FUTURE

Education programs (EP): 

CRAB - Toward a better quality of life through an earlier diagnosis
Program is focused on family physicians and key out-patients physicians responsible for recognizing the symptoms related to MM (specialists of rheumatology, neurology, orthopedic or nephrology).
Initiation: 2007
Duration: 2007-2011
Anticipated outcome:

• reduction of the late stage III from 70% to <50%
• reduction of irreversible deterioration at the time of diagnosis from 20% to <10%

Transfer of methods
Program is focused on the standardization of laboratory examination methods in multiple myeloma in Central and Eastern Europe (incl. Czech Republic, Slovakia, Poland and Hungary).
Guaranteed by Monoclonal Gammopathy and Multiple Myeloma Basic Research Centre
Initiation: 2006
Outcome:

• to gain recognition as a Centre of Excellence
• to help the others to quickly adopt specific effective examination methods in MM

International workshops:

• FISH in MM - Detection of chromosomal aberration (10/2006)
•  MACS & FISH in MM - From cell sorting to plasma cell identification (10/2007)

Register of Monoclonal Gammopathies (RMG register)

Project MGUS 2007 - "2000 data sets in 2 year"
Initiation: 2007
Data-info part: follow up steps

• retro/prospectively data collection of 2000 people with MGUS
• confirmation of the risk factors for progression to MM
• preparation of brochures and programs for:
  • health population with benign MGUS - "minimal program"
  • "high risk" MGUS including research projects and phase I/II trials

Targets:

• stop progression form high risk MGUS to MM
• find biological (genomic/proteomic/cytomic) markers of progression

Research part: utilization of substantive information from RMG register and evaluation of samples stored in MM bank from pts. with MGUS and MM.
Aims: 

1. Evaluation of pharmacogenomic  and  pharmacoproteomics for the determination of resistance and sensitivity to anti-myeloma drugs
2. Identification and validation of clinically applicable model for the selection of optimal anti-myeloma treatment on the basis of genomic and proteomic markers
3. Identification of proteome differences between benign and mclassant gammopathies 
4. Creation of new model superior to currently used systems for the identification of high-risk MGUS patients

|| Prohlášení || CMG sdružení | CMG nadační fond | Registr RMG | Projekt CRAB | Mnohočetný myelom | Studie / výzkum | Aktivity a události | Informace pro sponzory | Tiskové zprávy | Zpětné odkazy